Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04510311 | Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors | completed | Early Phase 1 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01873248 | Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective | completed | Early Phase 1 | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2024 |
| NCT05871320 | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms(TECANT) | completed | Early Phase 1 | 10 | Jagiellonian UniversityOTHER | 3 | Sep 29, 2023 | clinicaltrials |
| NCT03647657 | 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer | completed | Early Phase 1 | 8 | University Hospital, Basel, SwitzerlandOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03197012 | Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor | completed | Early Phase 1 | 10 | Thomas HopeOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04440956 | An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours | completed | Early Phase 1 | 10 | Clarity Pharmaceuticals LtdINDUSTRY | 0 | Jun 22, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2026source: clinicaltrials